Please login to the form below
Covid-19
This page shows the latest Covid-19 news and features for those working in and with pharma, biotech and healthcare.
Pfizer/BioNTech’s Omicron-adapted booster approved by FDA for young children
Pfizer and BioNTech’s Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine has been authorised by the US Food and Drug Administration (FDA) for emergency use as a single ... Recent real-world evidence has also shown the bivalent vaccine to be protective
Latest news
-
JCVI recommends spring COVID-19 booster for those at highest risk
The Joint Committee on Vaccination and Immunisation (JCVI) has advised the UK government that those at the highest risk of severe COVID-19 should be offered an extra booster vaccination this ... Scotland has yet to announce plans for its booster campaign.
-
Pfizer/BioNTech submit FDA application for Omicron-adapted booster for young children
Pfizer and BioNTech have submitted an application to the US Food and Drug Administration (FDA) for the emergency use of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine ... Vaccine manufacturers have been focused on the development of variant
-
FDA authorises first at-home COVID-19 and flu test for emergency use
positive COVID-19 samples and 99.9% of negative influenza B samples in symptomatic individuals. ... The inaccuracy of antigen COVID-19 tests makes such tests inadequate to use for early differential diagnosis of flu versus COVID-19.”.
-
Gilead reports positive real-world evidence for COVID-19 treatment Veklury
Gilead Sciences has reported positive real-world evidence for its COVID-19 treatment, Veklury (remdesivir), demonstrating a reduction in mortality and hospital readmission rates among all patients hospitalised with the virus. ... In a separate analysis,
-
Merck and Ridgeback’s COVID-19 pill fails to prevent infection within households
Lagevrio is already approved to treat certain patients with COVID-19 in several markets. ... The safety profile of Lagevrio was generally consistent with that observed in previously reported clinical studies and post-authorisation experience in the
More from news
Approximately 769 fully matching, plus 217 partially matching documents found.
Latest Intelligence
-
Next congress, please: making the most of virtual pharmaceutical congresses
We’ve all seen and likely had firsthand experience of the strain COVID-19 has placed upon our healthcare professionals (HCPs), providers and us as patients. ... But there are many other aspects of ‘being HCPs’ that go beyond front-line care where
-
The state of pharma customer experience
Instead, the industry faces an environment that is still adjusting after the shocks that COVID-19 brought. ... largest markets, despite Germany and France having largely ended their own COVID-19 restrictions by then.
-
Mental health post-COVID-19: what are the consequences and lessons learned for healthcare?
Beyond the COVID-19 era: positive effects on people living with mental health conditions. ... Lessons learned: managing the ongoing implications of COVID-19 and preparing for the next pandemic.
-
A new age of innovation in healthcare
It is also important to ensure that the short-term reputational gains from creating and manufacturing COVID-19 vaccines is not lost over time.
-
Biosimilars and beyond: innovating for improved patient outcomes
Today, the healthcare industry continues to be met with extreme pressure – many countries worldwide are facing a potential ‘twindemic’ of seasonal flu and COVID-19, along with workforce shortages, and an
More from intelligence
Approximately 16 fully matching, plus 188 partially matching documents found.
Latest appointments
-
Hanover Health appoints James Mole as a director
During his time at NHS England, he also served as head of media over the course of the COVID-19 pandemic, supporting regular Downing Street press conferences and managing journalist enquiries. ... He also offered senior counsel to NHS leaders, including
-
Amanda Pritchard becomes NHS England’s first female chief executive
other staff have responded so magnificently to the COVID-19 pandemic,” said Pritchard. ... inevitably built up in the face of rising COVID-19 infections.
-
EFPIA appoints Hubertus von Baumbach as president
But COVID-19 has also underlined the critical importance of a strong and competitive research, development and medical innovation ecosystem to address major health challenges and drive economic growth.
-
ENGINE MHP+Mischief bolsters healthcare comms expertise with new senior hires
In this role, he oversaw all media relations for the UK’s COVID-19 vaccination programme, providing strategic advice to Vaccines Minister Nadhim Zahawi and Health and Social Care Secretary Matt
More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.
Latest from PMHub
-
WHY ARE PATIENT SUPPORT PROGRAMMES NOT WORKING?
Seb Tucknott CEO &Co-founder IBD Relief. Although these types of PSPs are still useful and have merit, with the current focus on technology and COVID-19 changing the healthcare landscape, ... Likewise, CLLSupport have moved their events online due to
-
Could femtech be the answer to the gender health gap?
While the COVID-19 pandemic has accelerated the adoption of digital practices across many areas of healthcare (it is estimated that digital adoption for both consumers and businesses moved forward by ... MobiHealthNews. Published August 12, 2021.
-
The dissemination and consumption of medical literature is evolving
QxMD, part of the WebMD Health Network discusses how they are going to evolve its publication solution, Read by QxMD in 2023. Traditionally, new scientific data would be presented at specialist congresses, subsequently published in a peer-reviewed
-
Action on Anti-microbial resistance: Will the UK rise to the challenge
The COVID-19 pandemic and lockdown measures are likely to have affected AMR data, making it difficult to assess progress. ... The UK Government’s new consultation for the 2024-2029 AMR National Action Plan offers a unique opportunity to discuss progress
-
Bedrock Healthcare Communications is proud to accept the PMEA for Agility in Pharma Market Excellence
During the COVID-19 pandemic, multiple sclerosis (MS) experts were receiving many questions regarding the safety and efficacy of COVID-19 vaccination in patients receiving treatment for MS. ... A further 28 MS experts from 19 countries also voted on the
More from PMHub
Approximately 91 fully matching, plus 277 partially matching documents found.
Subscribe to our email news alerts
-
Senior Medical Writer
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Pharmacovigilance Project Lead
- Highly competitive salary
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- LEO Pharma enters clinical trial partnership with ICON
- Results for Astellas’ non-hormonal menopause drug published in The Lancet
- Roche’s Polivy backed by FDA Advisory Committee for lymphoma therapy
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- How to create content for health professionals
- Sanofi to cut US insulin prices by up to 78% in January 2024
- Pfizer and Astellas’ Xtandi shows promise in phase 3 prostate cancer study
- 2023 PM Society Awards – winners announced
- Next congress, please: making the most of virtual pharmaceutical congresses
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- Locus Biosciences announces first patient treated in urinary tract infection trial
- A relentless commitment to neuroscience
- AstraZeneca announces major expansion of Canadian research footprint
- BMS will not launch cancer drug Opdualag in Germany due to pricing pressures
- Neurodiversity and healthcare communications – do we know enough and do we do enough?
PMHub
Six Degrees Medical Consulting
For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...
Latest intelligence
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
- WHY ARE PATIENT SUPPORT PROGRAMMES NOT WORKING?
- By offering patients knowledge, skills and confidence, they empower patients to be more actively involved in their health. Holistic support can help tackle adherence, mental health or anything else patients...
- THE EVOLVING ROLE OF PROCUREMENT?
- Procurement is evolving to reinforce its position as a strategic enabler of company growth. How can agency partners organisations to realise this?...
